A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards such as FOLFOX, FOLFIRI, and nal-IRI/FL, while maintaining manageable toxicity levels. These findings suggest that FOLFIRINOX could serve as a promising second-line treatment option for patients with advanced BTC following first-line chemotherapy failure, warranting further validation through prospective clinical studies.

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic resistance. However, the molecular mechanisms driving these processes are still not fully understood.Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic resistance. However, the molecular mechanisms driving these processes are still not fully understood.

For decades, kinase inhibitors have been a mainstay of cancer therapy, designed to switch off enzymes that fuel uncontrolled cell growth. But new research shows that these drugs often go further: they can also cause the very proteins they target to be dismantled by the cell, making them yet another tool for the emerging field of Targeted Protein Degradation (TPD). In a new study published in Nature, scientists at CeMM and AITHYRA in Vienna, and the IRB in Barcelona, with partners across Europe, the US and China, have now mapped this effect systematically, uncovering a widespread but overlooked phenomenon in pharmacology.